<unk>  a concentrate of proteolytic enzymes from the pineapple plant, is used in medicine. It is approved in the European Union for the debridement (removal of eschar, that is dead and damaged tissue) of severe burn wounds under the brand name NexoBrid. In the US, it has completed Phase III clinical trials and has the tentative trade name Debrase. It was developed by MediWound, Germany; and Teva is responsible for development and marketing in the US. The medicine has been granted orphan drug status by the European Medicines Agency (EMA). In other contexts,<unk> has been researched for possible anti-inflammatory effects in treating a range of conditions or diseases, but results of these studies are mixed and regarded as preliminary.
Bromelain 
Tetrodocain
Ibogaine
Noribogaine
Pramocaine
Iontocaine
Oxybuprocaine
Levobupivacaine